Skip to main content

Table 3 Summary of on-therapy adverse events occurring in ≥10% of patients in either of the treatment arms (Chinese safety population)

From: Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies

Adverse eventPazopanib
N = 109
n (%)
Sunitinib
N = 100
n (%)
Patients with any event108 (> 99)99 (99)
Hypertension65 (60)50 (50)
Diarrhea57 (52)37 (37)
Palmar-plantar erythrodysesthesia syndrome (HFS)52 (48)57 (57)
Hair color changes47 (43)13 (13)
Alanine aminotransferase increased45 (41)32 (32)
Fatigue43 (39)41 (41)
Aspartate aminotransferase increased41 (38)32 (32)
Decreased appetite41 (38)32 (32)
Proteinuria39 (36)39 (39)
Leukopenia33 (30)43 (43)
Blood bilirubin increased27 (25)21 (21)
Neutropenia26 (24)36 (36)
Neutrophil count decreased25 (23)40 (40)
Platelet count decreased23 (21)39 (39)
Blood creatinine increased21 (19)32 (32)
Thrombocytopenia20 (18)39 (39)
Nausea19 (17)15 (15)
Vomiting19 (17)9 (9)
Hypothyroidism18 (17)23 (23)
Mouth ulceration17 (16)25 (25)
White blood cell count decreased17 (16)33 (33)
Eyelid edema16 (15)28 (28)
Abdominal pain upper15 (14)7 (7)
Bilirubin conjugated increased15 (14)6 (6)
Blood bilirubin unconjugated increased15 (14)8 (8)
Hemoglobin decreased13 (12)31 (31)
Skin hypopigmentation13 (12)3 (3)
Blood triglycerides increased12 (11)14 (14)
Blood lactate dehydrogenase increased9 (8)18 (18)
Epistaxis9 (8)11 (11)
Hypogeusia9 (8)12 (12)
Pain in extremity9 (8)12 (12)
Rash9 (8)14 (14)
Blood thyroid stimulating hormone increased8 (7)19 (19)
Anemia7 (6)25 (25)
Dysgeusia6 (6)12 (12)
Peripheral edema6 (6)14 (14)
Blood cholesterol increased5 (5)10 (10)
Stomatitis4 (4)12 (12)
Facial edema3 (3)17 (17)
Yellow skin3 (3)22 (22)
Nasopharyngitis2 (2)10 (10)
Xanthochromia1 (< 1)10 (10)
  1. HFS Hand-foot syndrome